Abstract
Chikungunya can have longstanding effects on health and quality of life. Alongside the licensing of new chikungunya vaccines in the pipeline, it is important to understand the perspectives of stakeholders before vaccine rollout. Our study aim is to identify key programmatic considerations for chikungunya vaccine introduction in countries at risk of chikungunya outbreaks. We used purposive and snowball sampling to identify global, national, and subnational stakeholders from outbreak prone areas, including Latin America, Asia, and Africa. Semi-structured in-depth interviews were conducted and analysed using qualitative descriptive methods. We found that perspectives varied between tiers of stakeholders and geographies. Unknown disease burden, diagnostics, non-specific disease surveillance, undefined target populations for vaccination, and low disease prioritisation were critical challenges identified by stakeholders that need to be addressed to facilitate rolling out a chikungunya vaccine. Future investments should address these challenges to generate useful evidence for decision-making on new chikungunya vaccine introduction.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was funded by the International Vaccine Institute. HK is supported by the Vaccine Impact Modelling Consortium. OJB was supported by a UK Medical Research Council Career Development Award (MR/V031112/1). KA is supported by the Vaccine Impact Modelling Consortium (INV-034281) and the Japan Agency for Medical Research and Development (JP223fa627004).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this project was received from the London School of Hygiene and Tropical Medicine in January 2023, project reference number 28292.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data sharing
Stakeholders consented to interviews understanding that the data collected would not be shared publicly nor include names and organisations’ names. The data used in this analysis will be shared anonymously upon reasonable request.
